Evaluation of the Usefulness of Adalimumab in Patients with Psoriatic arthritis
- Conditions
- psoriatic arthritis
- Registration Number
- JPRN-UMIN000016543
- Lead Sponsor
- agoya City University Graduate School of Medical Sciences, Department of Geriatric and Environmental Dermatology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Not provided
(1)Patients with other active skin disease possibly disturbing evaluation of psoriasis-related skin symptoms (2)Patients having received intraarticular or intratendinous injection of steroid with 4 weeks before the start of this study (3)Patients having received biological preparations during the period specified below: Infliximab: within 8 weeks before the start of this study Ustekinumab: within 12 weeks before the start of this study Other biological preparations (including drugs on clinical trial): within 24 weeks before the start of this study (4)Patients receiving ultraviolet ray therapy or using ciclosporin or etretinate at the start of this study of this study (5)Patients with serious infection (sepsis, etc.) (6)Patients with active tuberculosis (7)Patients with a history of hypersensitivity to any component of the study drug (8)Patients with demyelinating disease (multiple sclerosis, etc.) or its history (9)Patients with congestive heart failure (10)Other patients judged by the investigator or the like as inappropriate for this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method